Fig. 4

Sharp1 deletion attenuates MLL-AF6 AML progression. a Experimental strategy for replating and in vivo leukemia assays in Sharp1^+/+ or Sharp1^−/− hematopoietic stem/progenitor cells following retroviral transduction of MLL-AF6. b Kaplan–Meyer survival curve of sublethally irradiated congenic mice transplanted with 200,000 cells from (left panel) the first replate (right panel) and whole bone marrow cells isolated from leukemic recipients following the first transplant. Data includes at least two independent transplantation experiments. Statistical analysis was performed using Log-rank (Mantle-Cox) test. c Peripheral blood count and percentage of leukemia cells (CD45.2⁺ CD11b⁺) from the recipient mice (n = 17 per genotype) two months after primary transplant are shown. Statistical analysis was performed using Mann–Whitney U test, **p < 0.01, ***p < 0.001. All individual data points include three independent transplantation experiments and are presented as mean ± s.e.m. d Representative pictures of liver and spleen and Wright Giemsa staining of bone marrow (BM) cells from moribund leukemic mice. e Left panel: Differential count of Wright Giemsa-stained BM cells from moribund leukemic mice. Mybl myeloblasts, Myelo promyelocytes, myelocytes, and metamyelocytes, Band (seg) band and segmented neutrophils, Others lymphocytes and macrophages. Right panel: Percentage of CD11b high and Gr1 high cells in CD45.2⁺ BM cells are shown. The graph is present as mean ± s.e.m from three independent moribund leukemic mice